Press Releases
reVision Therapeutics Attends Stargardt’s Connected Community Zoom
October 4, 2023
On September 9th, reVision participated in the Stargardt’s Connected Community Zoom session. Dr. Paul Fehlner, co-founder and CEO of reVision, provided an overview of our lead program, REV-0100, for Stargardt disease, a rare pediatric retinal disease. . .
Aequus and reVision to Collaborate on Stargardt Disease Program
Aequus Gains Option for North American Commercial Rights
Aug 17, 2021
Aequus Pharmaceuticals Inc. (TSX-V: AQS) (OTCQB: AQSZF) ("Aequus") and reVision Therapeutics, Inc. ("reVision") announce a collaboration on the development of a therapy. . .
reVision Therapeutics Announces US FDA Grant of Rare Pediatric Disease and Orphan-Drug Designation for REV-0100 for the Treatment of Stargardt Disease
Oct 28, 2020
reVision Therapeutics, Inc. announced that the US Food and Drug Administration has granted the Company's request to designate REV-0100 as an Orphan-Drug and a. . .
reVision Therapeutics, Inc. Announces License with Cornell to Develop Treatment for Stargardt Disease
Sept 1, 2020
reVision Therapeutics, Inc. announced that it has signed an exclusive license agreement with Cornell University ("Cornell") for the development and commercialization of . . .
BIO-Europe® 2018: ReVision Therapeutics on potential fast path for drugs treating rare eye diseases
Nov 28, 2018
reVision Therapeutics, focused on repurposed drugs for the treatment of ophthalmic diseases, was selected for the Audience Choice award at the BIO-Europe 2018 Startup Slam. President and CEO Paul Fehlner explains. . .
Winner: Audience Award for Best Pitch at the BIO-Europe 2018 Startup Slam!
Nov 7, 2018
reVision Therapeutics was selected for the inaugural Audience Choice award at BIO-Europe Copenhagen’s Startup Slam.